Iovance Posts 61% Revenue Growth to $264M; FDA Fast Track for Lifileucel
Iovance Biotherapeutics reported a 61% year-over-year revenue increase to $264 million in 2025, with Q4 product sales rising 30% sequentially to $87 million driven by Amtagvi’s 112% sales jump. The FDA granted Fast Track status for lifileucel in non-small cell lung cancer targeting a 2027 launch, and the company achieved a 50% confirmed response rate in advanced soft tissue sarcoma trials.
1. Full Year 2025 Revenue Results
Iovance Biotherapeutics achieved total annual revenues of $264 million in 2025, a 61% increase over 2024, reflecting broad uptake of its lead product Amtagvi across both academic centers and expanding community-based Authorized Treatment Centers.
2. Q4 Performance and Amtagvi Success
In Q4 2025, product revenue reached $87 million, up 30% from Q3, with Amtagvi sales surging 112% year-over-year as manufacturing efficiencies improved and commercial distribution expanded.
3. FDA Fast Track and Pipeline Milestones
The FDA granted Fast Track designation to lifileucel for non-small cell lung cancer based on robust early data, supporting a projected 2027 launch and underscoring Iovance’s progress in solid tumor cell therapies.
4. Clinical Data in Sarcoma
Iovance reported a 50% confirmed response rate in advanced soft tissue sarcoma, with evidence of deepening and durable patient responses, bolstering its clinical profile across multiple tumor types.